OBJECTIVE: To study the efficacy of interferon beta (IFNβ) and glatiramer acetate (GA) related to the presence of oligoclonal M bands (OCMB) in the cerebrospinal fluid in relapsing-remitting multiple sclerosis (RRMS). METHOD: This is an observational, multicenter and retrospective study with prospectively collected data of patients that started treatment with IFNβ or GA. Treatment decision was made blinded to the OCMB status. Time to first attack after starting therapy was compared by using Kaplan-Meier curves, and adjustment by Cox regression analysis was performed. RESULTS: Two hundred and fifty-six patients entered in the study (141-55% received IFNβ; 115-45% received GA). After a mean follow-up of 41 and 65 months, 54.7% of patients remained free from further attacks (RF). The proportion of RF patients was higher in the GA group than in the IFNβ group (72.2 vs. 40.4%, p < 0.001). The IFNβ patients with OCMB+ presented the poorest response, 31.3% RF vs. 48.1% in IFNβ without OCMB, p = 0.03. CONCLUSION: OCMB in CSF could be a biomarker of treatment response in multiple sclerosis.
OBJECTIVE: To study the efficacy of interferon beta (IFNβ) and glatiramer acetate (GA) related to the presence of oligoclonal M bands (OCMB) in the cerebrospinal fluid in relapsing-remitting multiple sclerosis (RRMS). METHOD: This is an observational, multicenter and retrospective study with prospectively collected data of patients that started treatment with IFNβ or GA. Treatment decision was made blinded to the OCMB status. Time to first attack after starting therapy was compared by using Kaplan-Meier curves, and adjustment by Cox regression analysis was performed. RESULTS: Two hundred and fifty-six patients entered in the study (141-55% received IFNβ; 115-45% received GA). After a mean follow-up of 41 and 65 months, 54.7% of patients remained free from further attacks (RF). The proportion of RF patients was higher in the GA group than in the IFNβ group (72.2 vs. 40.4%, p < 0.001). The IFNβ patients with OCMB+ presented the poorest response, 31.3% RF vs. 48.1% in IFNβ without OCMB, p = 0.03. CONCLUSION:OCMB in CSF could be a biomarker of treatment response in multiple sclerosis.
Authors: I Bosca; L M Villar; F Coret; M J Magraner; M Simó-Castelló; J C Alvarez-Cermeño; B Casanova Journal: Mult Scler Date: 2010-06-10 Impact factor: 6.312
Authors: Loredana La Mantia; Carlo Di Pietrantonj; Marco Rovaris; Giulio Rigon; Serena Frau; Francesco Berardo; Anna Gandini; Anna Longobardi; Bianca Weinstock-Guttman; Alberto Vaona Journal: Cochrane Database Syst Rev Date: 2014-07-26
Authors: M Espiño; V Abraira; R Arroyo; L Bau; C Cámara; L Campos-Ruiz; B Casanova; C Espejo; O Fernández; A García-Merino; M I García-Sánchez; M Gómez; A Gosis; G Izquierdo; J Meca; X Montalban; F Morandeira; J Olascoaga; A Prada; E Quintana; Ll Ramió-Torrentà; A Rodríguez-Antigüedad; G Salgado; J L Santiago; E Sarasola; M Simó-Castelló; J C Alvarez-Cermeño; L M Villar Journal: Clin Chim Acta Date: 2014-08-08 Impact factor: 3.786
Authors: R H S R Roxburgh; S R Seaman; T Masterman; A E Hensiek; S J Sawcer; S Vukusic; I Achiti; C Confavreux; M Coustans; E le Page; G Edan; G V McDonnell; S Hawkins; M Trojano; M Liguori; E Cocco; M G Marrosu; F Tesser; M A Leone; A Weber; F Zipp; B Miterski; J T Epplen; A Oturai; P Soelberg Sørensen; E G Celius; N Téllez Lara; X Montalban; P Villoslada; A M Silva; M Marta; I Leite; B Dubois; J Rubio; H Butzkueven; T Kilpatrick; M P Mycko; K W Selmaj; M E Rio; M Sá; G Salemi; G Savettieri; J Hillert; D A S Compston Journal: Neurology Date: 2005-04-12 Impact factor: 9.910
Authors: Ryan D Schubert; Yang Hu; Gaurav Kumar; Spencer Szeto; Peter Abraham; Johannes Winderl; Joel M Guthridge; Gabriel Pardo; Jeffrey Dunn; Lawrence Steinman; Robert C Axtell Journal: J Immunol Date: 2015-02-02 Impact factor: 5.422
Authors: Lm Villar; N García-Barragán; M Espiño; E Roldán; Mc Sádaba; J Gómez-Rial; P González-Porqué; Jc Alvarez-Cermeño Journal: Mult Scler Date: 2007-10-17 Impact factor: 6.312
Authors: L D Jacobs; D L Cookfair; R A Rudick; R M Herndon; J R Richert; A M Salazar; J S Fischer; D E Goodkin; C V Granger; J H Simon; J J Alam; D M Bartoszak; D N Bourdette; J Braiman; C M Brownscheidle; M E Coats; S L Cohan; D S Dougherty; R P Kinkel; M K Mass; F E Munschauer; R L Priore; P M Pullicino; B J Scherokman; R H Whitham Journal: Ann Neurol Date: 1996-03 Impact factor: 10.422
Authors: Igal Rosenstein; Sofia Rasch; Markus Axelsson; Lenka Novakova; Kaj Blennow; Henrik Zetterberg; Jan Lycke Journal: Front Immunol Date: 2022-08-10 Impact factor: 8.786
Authors: Giancarlo Comi; Amit Bar-Or; Hans Lassmann; Antonio Uccelli; Hans-Peter Hartung; Xavier Montalban; Per Solberg Sørensen; Reinhard Hohlfeld; Stephen L Hauser Journal: Ann Neurol Date: 2020-11-04 Impact factor: 10.422